Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer

被引：2

作者：

Frehner, Lorenz ^{[1
]}

Haefliger, Simon ^{[1
]}

Cerciello, Ferdinando ^{[1
]}

Grob, Tobias ^{[2
]}

Schmid, Sabine ^{[1
]}

机构：

[1] Univ Bern, Bern Univ Hosp, Dept Med Oncol, Inselspital, Bern, Switzerland

[2] Univ Bern, Inst Tissue Med & Pathol, Bern, Switzerland

来源：

CASE REPORTS IN ONCOLOGY | 2023年 / 16卷 / 01期

关键词：

Non-small cell lung cancer; Targeted therapy; NTRK2; SOLID TUMORS; TRK; ENTRECTINIB; EFFICACY;

D O I：

10.1159/000533572

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these agents in patients with NSCLC and NTRK2 fusion are available. We present a case of a female patient with NTRK2-positive NSCLC with a complete ongoing response on therapy with larotrectinib, suggesting efficacy of first-generation TRK inhibitors also in NTRK2-positive NSCLC.

引用

页码：871 / 877

页数：7

共 33 条

[1] NTRK gene fusions as novel targets of cancer therapy across multiple tumour types [J].

Amatu, Alessio ;

Sartore-Bianchi, Andrea ;

Siena, Salvatore .

ESMO OPEN, 2016, 1 (02)

[2]

[Anonymous], 2012, LIVERTOX CLIN RES IN

[3] Resistance to TRK inhibition mediated by convergent MAPK pathway activation [J].

Cocco, Emiliano ;

Schram, Alison M. ;

Kulick, Amanda ;

Misale, Sandra ;

Won, Helen H. ;

Yaeger, Rona ;

Razavi, Pedram ;

Ptashkin, Ryan ;

Hechtman, Jaclyn F. ;

Toska, Eneda ;

Cownie, James ;

Somwar, Romel ;

Shifman, Sophie ;

Mattar, Marissa ;

Selcuklu, S. Duygu ;

Samoila, Aliaksandra ;

Guzman, Sean ;

Tuch, Brian B. ;

Ebata, Kevin ;

de Stanchina, Elisa ;

Nagy, Rebecca J. ;

Lanman, Richard B. ;

Houck-Loomis, Brian ;

Patel, Juber A. ;

Berger, Michael F. ;

Ladanyi, Marc ;

Hyman, David M. ;

Drilon, Alexander ;

Scaltriti, Maurizio .

NATURE MEDICINE, 2019, 25 (09) :1422-+

[4] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials [J].

Doebele, Robert C. ;

Drilon, Alexander ;

Paz-Ares, Luis ;

Siena, Salvatore ;

Shaw, Alice T. ;

Farago, Anna F. ;

Blakely, Collin M. ;

Seto, Takashi ;

Cho, Byung Chul ;

Tosi, Diego ;

Besse, Benjamin ;

Chawla, Sant P. ;

Bazhenova, Lyudmila ;

Krauss, John C. ;

Chae, Young Kwang ;

Barve, Minal ;

Garrido-Laguna, Ignacio ;

Liu, Stephen V. ;

Conkling, Paul ;

John, Thomas ;

Fakih, Marwan ;

Sigal, Darren ;

Loong, Herbert H. ;

Buchschacher, Gary L., Jr. ;

Garrido, Pilar ;

Nieva, Jorge ;

Steuer, Conor ;

Overbeck, Tobias R. ;

Bowles, Daniel W. ;

Fox, Elizabeth ;

Riehl, Todd ;

Chow-Maneval, Edna ;

Simmons, Brian ;

Cui, Na ;

Johnson, Ann ;

Eng, Susan ;

Wilson, Timothy R. ;

Demetri, George D. .

LANCET ONCOLOGY, 2020, 21 (02) :271-282

[5] Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors [J].

Doz, Francois ;

van Tilburg, Cornelis M. ;

Geoerger, Birgit ;

Hojgaard, Martin ;

Ora, Ingrid ;

Boni, Valentina ;

Capra, Michael ;

Chisholm, Julia ;

Chung, Hyun Cheol ;

DuBois, Steven G. ;

Gallego-Melcon, Soledad ;

Gerber, Nicolas U. ;

Goto, Hiroaki ;

Grilley-Olson, Juneko E. ;

Hansford, Jordan R. ;

Hong, David S. ;

Italiano, Antoine ;

Kang, Hyoung Jin ;

Nysom, Karsten ;

Thorwarth, Anne ;

Stefanowicz, Joanna ;

Tahara, Makoto ;

Ziegler, David S. ;

Gavrilovic, Igor T. ;

Norenberg, Ricarda ;

Dima, Laura ;

De la Cuesta, Esther ;

Laetsch, Theodore W. ;

Drilon, Alexander ;

Perreault, Sebastien .

NEURO-ONCOLOGY, 2022, 24 (06) :997-1007

[6] Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children [J].

Drilon, A. ;

Laetsch, T. W. ;

Kummar, S. ;

DuBois, S. G. ;

Lassen, U. N. ;

Demetri, G. D. ;

Nathenson, M. ;

Doebele, R. C. ;

Farago, A. F. ;

Pappo, A. S. ;

Turpin, B. ;

Dowlati, A. ;

Brose, M. S. ;

Mascarenhas, L. ;

Federman, N. ;

Berlin, J. ;

El-Deiry, W. S. ;

Baik, C. ;

Deeken, J. ;

Boni, V. ;

Nagasubramanian, R. ;

Taylor, M. ;

Rudzinski, E. R. ;

Meric-Bernstam, F. ;

Sohal, D. P. S. ;

Ma, P. C. ;

Raez, L. E. ;

Hechtman, J. F. ;

Benayed, R. ;

Ladanyi, M. ;

Tuch, B. B. ;

Ebata, K. ;

Cruickshank, S. ;

Ku, N. C. ;

Cox, M. C. ;

Hawkins, D. S. ;

Hong, D. S. ;

Hyman, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (08) :731-739

[7]

Drilon AE, 2022, J CLIN ONCOL, V40

[8] Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion [J].

Farago, Anna F. ;

Taylor, Martin S. ;

Doebele, Robert C. ;

Zhu, Viola W. ;

Kummar, Shivaani ;

Spira, Alexander, I ;

Boyle, Theresa A. ;

Haura, Eric B. ;

Arcila, Maria E. ;

Benayed, Ryma ;

Aisner, Dara L. ;

Horick, Nora K. ;

Lennerz, Jochen K. ;

Le, Long P. ;

Iafrate, A. John ;

Ou, Sai-Hong, I ;

Shaw, Alice T. ;

Mino-Kenudson, Mari ;

Drilon, Alexander .

JCO PRECISION ONCOLOGY, 2018, 2

[9] EML4-ALK Variant Affects ALK Resistance Mutations [J].

Fruh, Martin ;

Peters, Solange .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) :1257-+

[10] Molecular characterization of cancers with NTRK gene fusions [J].

Gatalica, Zoran ;

Xiu, Joanne ;

Swensen, Jeffrey ;

Vranic, Semir .

MODERN PATHOLOGY, 2019, 32 (01) :147-153

← 1 2 3 4 →